BioCryst Pharmaceuticals (MEX:BCRX) Cyclically Adjusted FCF per Share: MXN-10.65 (As of Mar. 2026)


MEX:BCRX BioCryst Pharmaceuticals Inc MEX:BCRX
56 GF Score
Price MXN182.00
GF Value MXN218.05
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Cyclically Adjusted FCF per Share?

BioCryst Pharmaceuticals MEX:BCRX -6.67% 56 Cyclically Adjusted FCF per Share is MXN-10.65 as of Mar. 2026. GuruFocus rates MEX:BCRX with a GF Score™ of 56/100 and a GF Value™ of MXN218.05 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioCryst Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was MXN-4.629. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN-10.65 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 8.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 1.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioCryst Pharmaceuticals was 8.30% per year. The lowest was -4.60% per year. And the median was -0.85% per year.

As of today (2026-07-11), BioCryst Pharmaceuticals's current stock price is MXN182.00. BioCryst Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was MXN-10.65. BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


BioCryst Pharmaceuticals  (MEX:BCRX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioCryst Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


BioCryst Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Cyclically Adjusted FCF per Share Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.81 -14.80 -15.40 -16.08 -12.47

BioCryst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.53 -17.85 -16.39 -12.47 -10.65

MEX:BCRX vs SUPN, PBH, AMLX: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


MEX:BCRX
56GF Score
BioCryst Pharmaceuticals Inc MEX:BCRX
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioCryst Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-4.629/330.2130*330.2130
=-4.629

Current CPI (Mar. 2026) = 330.2130.

BioCryst Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -3.268 241.018 -4.477
201609 -4.651 241.428 -6.361
201612 -1.636 241.432 -2.238
201703 -2.137 243.801 -2.894
201706 -2.178 244.955 -2.936
201709 -2.740 246.819 -3.666
201712 -2.119 246.524 -2.838
201803 -3.628 249.554 -4.801
201806 -2.801 251.989 -3.671
201809 -6.224 252.439 -8.142
201812 -4.305 251.233 -5.658
201903 -4.770 254.202 -6.196
201906 -4.281 256.143 -5.519
201909 -4.956 256.759 -6.374
201912 -1.510 256.974 -1.940
202003 -3.559 258.115 -4.553
202006 -4.445 257.797 -5.694
202009 -4.809 260.280 -6.101
202012 -4.806 260.474 -6.093
202103 -7.044 264.877 -8.782
202106 -2.931 271.696 -3.562
202109 -2.714 274.310 -3.267
202112 -3.786 278.802 -4.484
202203 -8.422 287.504 -9.673
202206 -3.035 296.311 -3.382
202209 -3.524 296.808 -3.921
202212 -2.542 296.797 -2.828
202303 -4.558 301.836 -4.987
202306 -1.748 305.109 -1.892
202309 -1.918 307.789 -2.058
202312 -0.798 306.746 -0.859
202403 -4.343 312.332 -4.592
202406 -0.135 314.175 -0.142
202409 0.779 315.301 0.816
202412 -0.592 315.605 -0.619
202503 -2.629 319.799 -2.715
202506 3.521 322.561 3.605
202509 3.360 324.800 3.416
202512 23.908 324.054 24.362
202603 -4.629 330.213 -4.629

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN-10.65 mean?
BioCryst Pharmaceuticals (MEX:BCRX) has a Cyclically Adjusted FCF per Share of MXN-10.65 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioCryst Pharmaceuticals and its competitors.
Is BioCryst Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
BioCryst Pharmaceuticals' current Cyclically Adjusted FCF per Share is MXN-10.65. Overall, BioCryst Pharmaceuticals has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Cyclically Adjusted FCF per Share compare to SUPN and PBH?
BioCryst Pharmaceuticals' Cyclically Adjusted FCF per Share of MXN-10.65 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioCryst Pharmaceuticals and its competitors. BioCryst Pharmaceuticals's current Cyclically Adjusted FCF per Share is MXN-10.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (MEX:BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN218.05, compared to a current price of MXN182.00 — trading 16.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN-10.65. BioCryst Pharmaceuticals' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BioCryst Pharmaceuticals (MEX:BCRX), the current Cyclically Adjusted FCF per Share is MXN-10.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (MEX:BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of MXN182.00 is trading 16.5% below its estimated GF Value™ of MXN218.05. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:BCRX:

  • Cyclically Adjusted FCF per Share: MXN-10.65
  • GF Value™: MXN218.05 vs. price of MXN182.00 (16.5% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the MEX:BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:USABO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
56GF Score

Get the complete analysis for MEX:BCRX

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN182.00
Price
MXN218.05
GF Value